tiprankstipranks
Trending News
More News >
Quanterix Corporation (QTRX)
NASDAQ:QTRX
US Market
Advertisement

Quanterix (QTRX) AI Stock Analysis

Compare
368 Followers

Top Page

QTRX

Quanterix

(NASDAQ:QTRX)

Rating:50Neutral
Price Target:
$5.50
▼(-0.18%Downside)
Quanterix's overall score is primarily influenced by its financial performance, which shows revenue growth but struggles with profitability and cash flow. Technical indicators point to bearish trends, and valuation metrics underscore current financial challenges. However, strategic initiatives and mergers offer potential for future growth.
Positive Factors
Cost Synergies
QTRX now expects to realize $55M in cost synergies with AKYA to maintain 2026 cash flow profitability target, driven by facility consolidation and deduplication of G&A and sales support.
Insider Activity
Recent insider purchases could suggest these individuals believe the stock is undervalued.
Product Launches
New product launches and benefits from the Akoya acquisition should drive stronger performance and valuation levels higher for QTRX over time.
Negative Factors
Acquisition Integration Risks
The acquisition adds integration risks to an already challenging macro backdrop and reduces cash flexibility for QTRX.
Alzheimer's Diagnostics Competition
There are risks of QTRX falling behind in the Alzheimer's diagnostics market, with competitors already obtaining or planning FDA approvals.
Macro Headwinds
Macro headwinds and continued NIH funding noise have led to relatively flat consumables and a significant sequential decrease in instrument revenue.

Quanterix (QTRX) vs. SPDR S&P 500 ETF (SPY)

Quanterix Business Overview & Revenue Model

Company DescriptionQuanterix Corporation is a life sciences company specializing in ultra-sensitive biomarker detection technology. The company operates primarily in the biotechnology and diagnostics sectors. Its flagship product is the Simoa (Single Molecule Array) platform, which enables researchers to detect and quantify proteins and other biomarkers in various sample types at significantly lower concentrations than traditional methods. Quanterix's technology is used in a wide range of applications, including neurology, oncology, and infectious diseases, providing critical insights for both research and clinical diagnostics.
How the Company Makes MoneyQuanterix generates revenue through the sale of its Simoa platform, which includes instruments, consumables, and reagent kits essential for biomarker detection and analysis. The company also earns income from service agreements, offering customized assay development and sample testing services to pharmaceutical companies, academic institutions, and research organizations. Additionally, Quanterix partners with other companies and institutions to leverage its technology in clinical trials and research studies, providing a further revenue stream through collaborative agreements and licensing deals.

Quanterix Earnings Call Summary

Earnings Call Date:May 12, 2025
(Q1-2025)
|
% Change Since: -3.84%|
Next Earnings Date:Aug 11, 2025
Earnings Call Sentiment Neutral
Quanterix demonstrated resilience in consumables and strategic advancements, such as new product launches and significant merger synergies, but faced challenges with declining total revenue, increased expenses, and macroeconomic pressures leading to a more conservative revenue outlook.
Q1-2025 Updates
Positive Updates
Record Consumables Revenue
Quanterix recorded its highest consumables quarter, with consumables revenue reaching $18.1 million, up 6% from the previous year.
Strategic Initiatives and Product Launches
The company launched four new immunology assays, building on 20 new assays introduced last year, and plans to release the next-gen platform Simoa ONE by year-end.
Akoya Biosciences Merger Synergies
The merger with Akoya is expected to increase Quanterix's shareholder ownership from 70% to 84% and contribute significantly to top-line and gross profit dollars.
Operational Efficiency and Cost Savings
Quanterix announced a $30 million core operating cost reduction, scaling to $55 million annualized savings by 2026, contributing to a path towards positive cash flow.
Negative Updates
Overall Revenue Decline
Total revenue for Q1 2025 was $30.3 million, a decrease of 5% compared to the prior year, with a significant decline in Accelerator lab revenue by 36%.
Conservative Revenue Guidance Revision
Revenue guidance for 2025 was revised to a decline of 5% to 13%, reflecting broader macroeconomic pressures, particularly in academic funding and pharma spending.
Increased Operating Expenses
GAAP operating expenses for the quarter increased by $9.1 million due to acquisition and integration expenses, leading to an adjusted EBITDA loss of $11.3 million.
Challenges in Academic Funding
A 20% reduction in NIH funding levels is anticipated, impacting revenues indexed to U.S. academic customers.
Company Guidance
During Quanterix Corporation's first quarter 2025 earnings call, several key financial metrics and strategic updates were discussed. The company reported a revenue of $30.3 million, representing a 5% decline year-over-year, but highlighted a record quarter for consumables, which grew by 6% to $18.1 million. The adjusted gross margin was approximately 50%, and adjusted cash usage improved by over 50%, amounting to $9 million. The company anticipates achieving positive cash flow by 2026, supported by a balance sheet exceeding $100 million. An amended merger with Akoya Biosciences was also announced, reducing the equity value by 67% to $66 million, while increasing Quanterix's shareholder ownership to 84% of the combined company. Additionally, the firm outlined strategic initiatives, including the upcoming launch of the Simoa ONE platform, which promises up to 10x the sensitivity of existing systems and aims to expand into immunology and oncology markets. The company has set a revenue guidance range for 2025 between $120 million and $130 million, factoring in challenges such as reduced NIH funding and pharma spending.

Quanterix Financial Statement Overview

Summary
Quanterix shows growth in revenue, but profitability is challenged by consistent negative net income and EBIT margins. While the balance sheet is robust with a low debt-to-equity ratio, negative operating and free cash flows highlight operational challenges.
Income Statement
50
Neutral
The company has shown revenue growth over several years, but profitability is a concern with consistently negative net income and EBIT margins. Gross profit margin is relatively stable, but high operating losses impact overall performance.
Balance Sheet
65
Positive
The balance sheet is solid with a healthy equity base and low debt levels, as indicated by a low debt-to-equity ratio. However, the company is not yet generating positive returns on equity due to ongoing net losses.
Cash Flow
45
Neutral
Operating cash flow remains negative, reflecting ongoing operational challenges. Free cash flow has shown some improvement but remains negative, indicating the company is not yet self-sustaining.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue135.44M122.37M104.95M110.56M86.38M
Gross Profit81.12M70.65M46.24M61.73M48.18M
EBITDA-44.26M-38.09M-65.73M-53.24M-27.27M
Net Income-38.53M-32.33M-96.70M-57.69M-31.53M
Balance Sheet
Total Assets406.53M425.01M434.20M501.53M271.05M
Cash, Cash Equivalents and Short-Term Investments289.12M321.32M338.74M396.46M181.58M
Total Debt37.37M41.46M44.10M21.89M30.80M
Total Liabilities76.50M78.08M75.26M60.58M64.92M
Stockholders Equity330.04M346.93M358.94M440.95M206.13M
Cash Flow
Free Cash Flow-38.53M-22.69M-60.00M-61.52M-27.30M
Operating Cash Flow-35.16M-18.90M-48.27M-47.91M-23.36M
Investing Cash Flow-82.27M-148.40M-11.21M-6.34M-626.00K
Financing Cash Flow456.00K2.69M2.31M270.80M96.24M

Quanterix Technical Analysis

Technical Analysis Sentiment
Negative
Last Price5.51
Price Trends
50DMA
5.70
Negative
100DMA
5.97
Negative
200DMA
8.44
Negative
Market Momentum
MACD
-0.15
Positive
RSI
44.60
Neutral
STOCH
45.71
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For QTRX, the sentiment is Negative. The current price of 5.51 is below the 20-day moving average (MA) of 6.05, below the 50-day MA of 5.70, and below the 200-day MA of 8.44, indicating a bearish trend. The MACD of -0.15 indicates Positive momentum. The RSI at 44.60 is Neutral, neither overbought nor oversold. The STOCH value of 45.71 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for QTRX.

Quanterix Risk Analysis

Quanterix disclosed 57 risk factors in its most recent earnings report. Quanterix reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Quanterix Peers Comparison

Overall Rating
UnderperformOutperform
Sector (46)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
70
Outperform
$156.32M23.3616.56%14.85%64.96%
59
Neutral
$259.98M-36.14%13.06%41.50%
55
Neutral
$158.08M-407.50%32.24%-66.93%
52
Neutral
$133.45M-60.68%19.84%5.77%
50
Neutral
$257.07M-14.51%7.71%-38.97%
47
Neutral
$164.93M-20.42%-18.80%26.16%
46
Neutral
C$201.68M-3.28-23.14%1.87%20.75%-0.36%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
QTRX
Quanterix
5.51
-10.05
-64.59%
ANIK
Anika Therapeutics
11.31
-16.59
-59.46%
CERS
Cerus
1.36
-1.02
-42.86%
ELMD
Electromed
18.64
3.36
21.99%
RCEL
Avita Medical
5.98
-4.15
-40.97%
LUNG
Pulmonx
3.32
-4.43
-57.16%

Quanterix Corporate Events

M&A TransactionsBusiness Operations and Strategy
Quanterix Announces Cost-Cutting Measures Post-Acquisition
Negative
Jul 24, 2025

On July 18, 2025, Quanterix Corporation announced a plan to reduce operating costs and preserve cash through a series of terminations as part of its integration strategy following the acquisition of Akoya Biosciences, Inc. This move is expected to result in annualized cash savings of approximately $18 million, primarily through headcount reductions to be completed by the third quarter of 2025. However, the company anticipates incurring expenses of around $2.5 million for severance. The actual financial impact may vary based on several assumptions, and Quanterix has acknowledged potential risks and uncertainties that could affect the expected outcomes.

The most recent analyst rating on (QTRX) stock is a Hold with a $8.00 price target. To see the full list of analyst forecasts on Quanterix stock, see the QTRX Stock Forecast page.

Executive/Board ChangesBusiness Operations and Strategy
Quanterix Announces Executive Termination for Cost Savings
Neutral
Jul 18, 2025

On July 14, 2025, Quanterix Corporation announced a plan to terminate certain executives of its newly acquired subsidiary, Akoya Biosciences, Inc., as part of an integration strategy to achieve cost savings and operational efficiencies. The move is expected to result in annual cash savings of approximately $2.8 million, although it will incur expenses of around $3.3 million in 2025 for severance payments. The company acknowledges that actual results may vary from these estimates and additional charges could arise.

The most recent analyst rating on (QTRX) stock is a Hold with a $7.00 price target. To see the full list of analyst forecasts on Quanterix stock, see the QTRX Stock Forecast page.

Executive/Board ChangesM&A Transactions
Quanterix Completes Acquisition of Akoya Biosciences
Positive
Jul 8, 2025

On July 8, 2025, Quanterix Corporation completed its acquisition of Akoya Biosciences, creating a comprehensive platform for measuring biomarkers across blood and tissue. This acquisition is expected to expand Quanterix’s market from $1 billion to $5 billion and accelerate its path to profitability by 2026. As part of the merger, Akoya designated Scott Mendel and Myla Lai-Goldman, MD, to join Quanterix’s Board of Directors, replacing Martin D. Madaus, PhD, and Sarah Hlavinka, who resigned on July 7, 2025. The merger positions Quanterix as a scaled leader in early disease detection for neurology, oncology, and immunology markets.

The most recent analyst rating on (QTRX) stock is a Hold with a $17.00 price target. To see the full list of analyst forecasts on Quanterix stock, see the QTRX Stock Forecast page.

Shareholder Meetings
Quanterix Revises Deadlines for Stockholder Proposals
Neutral
Jul 1, 2025

On June 26, 2025, Quanterix Corporation’s board announced that the 2025 Annual Meeting of Stockholders will be held virtually on September 23, 2025. Due to the meeting’s date being more than 30 days from the previous year’s meeting, deadlines for stockholder proposals and nominations have been revised, with new deadlines set for July 11 and July 25, 2025, to comply with SEC rules and the company’s bylaws.

The most recent analyst rating on (QTRX) stock is a Hold with a $17.00 price target. To see the full list of analyst forecasts on Quanterix stock, see the QTRX Stock Forecast page.

M&A TransactionsBusiness Operations and StrategyFinancial Disclosures
Quanterix Approves Cost-Reduction Plan Amidst Strategic Moves
Neutral
May 12, 2025

On May 7, 2025, Quanterix‘s Board of Directors approved a cost-reduction plan to save $15 million in 2025, with annualized savings of $30 million. This includes a significant reduction in workforce, expected to be completed by the end of the second quarter of 2025. Additionally, Quanterix announced a strategic move to integrate its Simoa® ONE assay kits with over 20,000 flow cytometers globally, enhancing its market reach and reducing the need for new equipment purchases. The company also reported a net loss for the first quarter of 2025 but is implementing measures to achieve positive cash flow by 2026, including a merger with Akoya Biosciences, expected to close in June 2025.

The most recent analyst rating on (QTRX) stock is a Hold with a $17.00 price target. To see the full list of analyst forecasts on Quanterix stock, see the QTRX Stock Forecast page.

M&A TransactionsBusiness Operations and Strategy
Quanterix Revises Merger Terms with Akoya Biosciences
Positive
Apr 29, 2025

On April 28, 2025, Quanterix Corporation announced an amended merger agreement with Akoya Biosciences, revising the terms of their previously announced merger. Under the new terms, Quanterix will issue fewer shares and pay $20 million in cash to Akoya shareholders, with Quanterix shareholders owning 84% of the combined entity. This strategic move aims to create value for shareholders and leverage combined resources to drive synergies and expedite profitability. The merger is expected to close in the second quarter of 2025, pending Akoya shareholder approval and other customary conditions.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 25, 2025